AMICUS THERAPEUTICS, INC. (FOLD) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-04-27

AMICUS THERAPEUTICS, INC. (FOLD) has filed 14 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-04-27. 2 Form 8-K material event filings were reported by FOLD in the last 90 days. InsiderAlpha tracks every FOLD SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About AMICUS THERAPEUTICS, INC. (FOLD)

SEC CIK	0001178879

90-Day SEC Filing Activity

Form 4 filings (90d)	14
Form 8-K filings (90d)	2
Latest Form 4 filing	2026-04-27

Recent FOLD Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-04-27	RAAB MICHAEL	Insider	D — Derivative transaction	115.9K	$14.50	$1.68M	SEC
2026-04-27	ROBERTS EIRY	Insider	D — Derivative transaction	76.3K	$14.50	$1.11M	SEC
2026-04-27	WHITMAN BURKE W	Insider	D — Derivative transaction	118.6K	$14.50	$1.72M	SEC
2026-04-27	Kelly Michael Aaron	Insider	D — Derivative transaction	72.5K	$14.50	$1.05M	SEC
2026-04-27	Campbell Bradley L	President and CEO	D — Derivative transaction	1.01M	$14.50	$14.63M	SEC
2026-04-27	WHEELER CRAIG A	Insider	D — Derivative transaction	84.6K	$14.50	$1.23M	SEC
2026-04-27	Rosenberg Ellen	Chief Legal Officer	D — Derivative transaction	15.0K	$14.50	$218K	SEC
2026-04-27	MCGLYNN MARGARET G	Insider	D — Derivative transaction	94.6K	$14.50	$1.37M	SEC
2026-04-27	Bleil Lynn Dorsey	Insider	D — Derivative transaction	113.9K	$14.50	$1.65M	SEC
2026-04-27	SBLENDORIO GLENN	Insider	D — Derivative transaction	142.6K	$14.50	$2.07M	SEC
2026-04-27	Rosenberg Ellen	Chief Legal Officer	D — Derivative transaction	463.9K	$14.50	$6.73M	SEC
2026-04-27	Harford Simon N.R.	Chief Financial Officer	D — Derivative transaction	143.6K	$14.50	$2.08M	SEC
2026-04-27	Clark David Michael	Chief People Officer	D — Derivative transaction	221.8K	$14.50	$3.22M	SEC
2026-04-27	Castelli Jeff	Chief Development Officer	D — Derivative transaction	427.1K	$14.50	$6.19M	SEC
2026-04-27	Prout Samantha	Chief Accounting Officer	D — Derivative transaction	126.0K	$14.50	$1.83M	SEC

All transactions sourced from SEC EDGAR Form 4 filings for AMICUS THERAPEUTICS, INC. (FOLD). Updated in real time as new filings are submitted to the SEC.

Most-Active FOLD Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
SBLENDORIO GLENN	10	$2.07M
WHEELER CRAIG A	10	$1.23M
MCGLYNN MARGARET G	10	$1.37M
RAAB MICHAEL	10	$1.68M
Bleil Lynn Dorsey	9	$1.65M

Recent FOLD Form 8-K Material Events

2026-04-27 — Item 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01 · Acquisition · neutral [SEC]
Amicus Therapeutics completed its merger with BioMarin Pharmaceutical Inc. on April 27, 2026, becoming a wholly owned subsidiary of BioMarin. Shareholders received $14.50 per share in cash consideration. This is an administrative closing of a previously announced deal from Decemb
2026-04-23 — Item 8.01 · Acquisition · neutral [SEC]
Amicus Therapeutics announced that France's Ministry of Economics and Finance granted clearance for the previously announced BioMarin acquisition under French foreign direct investment screening procedures on April 23, 2026. This was the final regulatory condition required for cl
2026-03-03 — Item 5.07, 9.01 · Acquisition · neutral [SEC]
Amicus Therapeutics stockholders voted to approve the company's pending acquisition by BioMarin Pharmaceutical Inc. at a special meeting held on March 3, 2026. The merger agreement was signed on December 19, 2025, and shareholders approved the transaction with 234.6 million votes
2026-02-20 — Item 2.02, 9.01 · Earnings · neutral [SEC]
Amicus Therapeutics announced its financial results for fiscal year 2025 on February 20, 2026 via press release. This is a routine annual earnings disclosure filed on Form 8-K Item 2.02, with the actual financial details contained in the referenced press release exhibit rather th

Recent Insider Filings

2026-04-27 — WHEELER CRAIG A (Insider)
2026-04-27 — MCGLYNN MARGARET G (Insider)
2026-04-27 — WHITMAN BURKE W (Insider)
2026-04-27 — SBLENDORIO GLENN (Insider)
2026-04-27 — ROBERTS EIRY (Insider)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in FOLD insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

FOLD Insider Trading — FAQ

What is the latest insider trade for FOLD?: AMICUS THERAPEUTICS, INC. (FOLD) had 14 insider filings in the last 90 days, with the most recent on 2026-04-27. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying FOLD stock?: 0 insider purchases of FOLD were filed in the last 90 days.
How many insiders are selling FOLD stock?: 0 insider sales of FOLD were filed in the last 90 days.
Where can I see FOLD SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every FOLD SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Learn More

Open the live FOLD dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.